Integrate personal growth into company development
Release time:
2020-07-22
Integrates Personal Growth into Company Development
Group Company 2018 Outstanding Salesman Peak Health Technology Company Cheng Guo
I joined Peak in 2016 4 to engage in domestic sales of plant extracts. My growth in the peak, basically with the health technology company plant extraction business development synchronization, participate in, witnessed the changes and progress of plant extraction business. In the past year, all of our colleagues have paid hard work, but also been recognized and rewarded. As a salesman, in order to achieve the sales target, I traveled more than 30 times throughout the year, attending exhibitions, visiting customers, inspecting trade product suppliers, and even acting as an escort for high-value goods. No pains, no gains. At the end of the year, I finally completed the responsibility system target signed with the company at the beginning of the year. The performance increased by 70% compared with 2017 , added 23 customers, and reserved nearly 20 potential customers, laying the foundation for the business development in 2019 .
Outlook 2019 , both for the company and for the individual.
First of all, we belong to an absolute sunrise industry with considerable prospects. Our company's three business sectors-Chinese herbal medicine, natural products, health food & health food, are all part of the big health industry chain. Intuitively, the "Health and Family Planning Commission" has been renamed the "Health Commission", and the macro-level attention to national health can be imagined. In the development of the industry, it is not difficult to see that traditional food manufacturing enterprises, pharmaceutical enterprises, and even real estate, industrial and mining enterprises are directly or indirectly laying out great health. We rely on Jianfeng Group, a listed company with strong performance and is committed to focusing on the layout of the health industry. In the future, we will face faster development, larger scale and better benefits.
Secondly, we should cherish job opportunities with gratitude. Although I read a lot of socio-economic data and analysis, I am not a threat theorist. I believe that all our rewards come from giving. After graduation, I worked in a private enterprise for five years, QC , QA , administration and sales all took turns. In the peak 2 years, what I personally felt was the protection and care of the enterprise for ordinary workers like me. On the high level, there is a sense of social responsibility and responsibility. As far as I am concerned, it is the protection of ordinary workers like me.
Third, set up small personal goals and help the company's big blueprint. Any great dream and goal is a qualitative leap from countless ordinary small goals and tasks through the accumulation of quantity. Take our company's business as an example: a qualified product requires our technicians to develop advanced technology, the supply department to purchase high-quality raw materials, reasonable storage by storage personnel, strict process operation by production colleagues, confirmation and release by inspection personnel, and a series of assistance from our administrative, financial, and environmental protection colleagues. Sales is only the first step. All the links are equally important and indispensable. Each of us sticks to, breaks through, and completes our own small goals in our own posts, and the company's big goals will surely be achieved.
follow the flies, doomed to decay; follow the bees, will harvest sweet. Integrating personal growth into the company's development, making progress with the company, creating performance and sharing results is the best way for an employee to realize his self-worth. (According to Cheng's speech at the summary and commendation meeting of Jianfeng Health Technology Company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page